Compare Live Nation Entertainment, Inc. (LYV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Live Nation Entertainment, Inc. trades at $178 (market cap $42.09B), while Regeneron Pharmaceuticals Inc trades at $672.4 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | REGN | |
|---|---|---|
Market Cap | $42.09B | $70.47B |
Sector | Industrials | Health |
52-Week High | $186.59 | $812.27 |
52-Week Low | $125.61 | $545.46 |
Enterprise Value | $43.59B | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation (LYV) trades at $180.84, up 0.34% today, with bullish technical signals from moving averages despite recent earnings misses. The company reported $25.2B revenue for 2025 with a slim 0.33% net margin, while valuation metrics show elevated P/E (117.49) and P/B (136.72) ratios. Recent news highlights executive share sales and ongoing legal scrutiny, though analyst consensus remains strongly bullish with an $200.20 price target.
Outlook remains mixed with strong revenue growth potential from concert demand and ticketing margins offset by profitability challenges and legal overhangs. The stock offers upside to analyst targets but faces execution risks amid high valuations and recent earnings volatility.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
